期刊文献+

卡维地洛治疗慢性充血性心力衰竭的研究 被引量:6

卡维地洛治疗慢性充血性心力衰竭的研究
下载PDF
导出
摘要 目的:探讨卡维地洛治疗慢性心力衰竭(CHF)的临床疗效。方法:收治CHF患者228例,随机分治疗组116例和对照组112例,治疗组在CHF标准治疗基础上,加用卡维地洛(2.5mg,2次/日开始逐渐递增至目标剂量,维持治疗),治疗前后分别评价心功能,左室射血分数(LVEF)。结果:经过卡维地洛治疗后,临床观察总有效率82.7%,明显优于对照值66.9%(P<0.05)。结论:在心衰治疗基础上应用卡维地洛安全有效,显著改善左室重塑。 Objective:To observe the efficacy of carvedilol in the treatment of chronic heart failure(CHF). Methods:228 CHF patients were randomly divided into the treatment group(n = 116) and the control group (n = 112). On the basis of the conventional treatment, the treatment group was given carvedilol ( from 2. 5 mg, bid, and then added gradually to the maximum tolerated dose or target dose,and kept this dose). After 12 months of treatment, the heart function and Left ventricular ejectfraction (LVEF) were observed in all cases. Results: After 12 months of treatment, the total effective rate of the treatment group(82.7% ) was higher than that of the control group(66.9% ) (P 〈 0. 05 ). Conclusion: In the treatment of CHF, the curative effect of carvedilol combined with the conventional treatment is better than that of the conventional treatment, and carvedilol therapy can improve left ventricular performance, reveres LV remodeling.
作者 王昭彬
出处 《中国社区医师(医学专业)》 2011年第26期22-23,共2页
关键词 卡维他洛 心力衰竭 充血性 card d he los congestive heart failure
  • 引文网络
  • 相关文献

参考文献5

二级参考文献52

  • 1胡咏梅,李法琦.氧化应激对心衰大鼠ET-1的影响及β-阻滞剂的干预[J].岭南心血管病杂志,2003,9(2):130-133. 被引量:7
  • 2诸骏仁,朱文玲,吴士尧,陈君柱,单江,蔡迺绳,吴学思,宋建平,李新立.卡维地洛治疗老年心力衰竭患者的耐受性研究[J].中华老年医学杂志,2005,24(7):489-491. 被引量:9
  • 3杨广,李小鹰.卡维地洛、美托洛尔对心衰大鼠心功能及体液因子的影响[J].山东医药,2006,46(13):4-6. 被引量:8
  • 4吴强,李隆贵,蔡运昌,杨天和,王晓峰,耿召华.卡维地洛对心衰大鼠心肌细胞间粘附分子-1表达的影响[J].中国分子心脏病学杂志,2002,2(5):21-24. 被引量:1
  • 5Colucei WS, Braunwald E. Pathophysiology of heart failure in braunwold E (eds) heart disease [C]. 5thed. Philadel Phia: WB Saunders Company, 1997 : 360.
  • 6Grimm D, Michaela H,Jabusch HC,et al. Extracelluar matrix proteins in cardiac fibroblasts derived from rat heart with chronic pressure overload: Effeels of hetar receptor blockadel[J].J Mol Cell Cardiol, 2001,33:487.
  • 7Gruseppe M, Guido G, Cristina G, et al. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage [J]. Hypertension, 1999,34 (4) : 724.
  • 8San F,Sawyer DB,Cheng DL,et al. Progressive left ventricular remodeling and apoptosis late after mycocardial infarction in mouse heart[J]. Am J Phys ol Cric Phys ol,2000,279(2):422.
  • 9Spallarossa P, Garibaldi S, Altieri P, et al. Carvedilol prevents doxorubicin- induced free radical release and apoptosis in cardiomyoeytes in vitro[J]. J Mol Cell Cardiol,2004,37(4) :837.
  • 10Yue TL, Ma XI, Wang XK,et al. Possible involvement of stress activated protein kinase signaling pathway and Fas receptor ex pression in prevention of ischemia/reperfusion induced cardiomyocyte apoptosis by carvedilol[J]. Cric Res, 1998,82(2) : 166.

共引文献49

同被引文献24

引证文献6

;
使用帮助 返回顶部